• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

Desogestrel for More Than Five Years May Up Risk of Intracranial Meningioma

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on June 25, 2025.

WEDNESDAY, June 25, 2025 -- Women who have used the oral contraceptive desogestrel (75 µg) for more than five continuous years have a small increased risk of intracranial meningioma, according to a study published online June 11 in The BMJ.

Noémie Roland, M.D., Ph.D., from the French National Health Insurance in Saint-Denis, and colleagues examined the risk of intracranial meningioma associated with oral contraceptives containing desogestrel, levonorgestrel, or levonorgestrel combined with estrogen. The study included 8,391 women in France who required surgery for intracranial meningioma in 2020 to 2023; each patient was matched to 10 women without intracranial meningioma.

The researchers found that in analyses of desogestrel according to duration of use, the odds ratio for risk of intracranial meningioma was not significant for short-term use but was significantly increased for prolonged use (odds ratio [OR], 1.32). Risk was driven by more than five continuous years of use (ORs, 1.51 and 2.09 for five to seven and seven or more years, respectively). Women with meningiomas located in the middle or anterior part of the skull base had greater excess risk (ORs, 1.90 and 1.50, respectively), as did those who had previously used a progestogen of known associated increased risk (OR, 3.30). Regardless of duration of use, there was no excess risk of intracranial meningioma for levonorgestrel (alone or combined with estrogen). For one intracranial meningioma requiring surgery, the estimated number needed to harm with desogestrel was 67,300 women.

"It is already common knowledge that stopping cyproterone, nomegestrol, chlormadinone, promegestone, medroxyprogesterone, or medrogestone precludes the need for surgery," Gilles Reuter, M.D., of Centre Hospitalier Universitaire de Liège in Belgium, writes in an accompanying editorial. "Now we know that stopping desogestrel may also avoid unnecessary potentially harmful treatments."

Abstract/Full Text

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted June 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.